[go: up one dir, main page]

MX2020006645A - Preparacion de absorcion percutanea para el tratamiento de la demencia que contiene donepezilo. - Google Patents

Preparacion de absorcion percutanea para el tratamiento de la demencia que contiene donepezilo.

Info

Publication number
MX2020006645A
MX2020006645A MX2020006645A MX2020006645A MX2020006645A MX 2020006645 A MX2020006645 A MX 2020006645A MX 2020006645 A MX2020006645 A MX 2020006645A MX 2020006645 A MX2020006645 A MX 2020006645A MX 2020006645 A MX2020006645 A MX 2020006645A
Authority
MX
Mexico
Prior art keywords
treatment
dementia
transdermal absorption
donepezil
absorption agent
Prior art date
Application number
MX2020006645A
Other languages
English (en)
Inventor
Sun - Woo Jang
Chang - Yell Shin
Jeon - Soo KIM
Hae - Sun KIM
Kwang - Ho Cha
Hyun - Jung KIM
Masaoki Goto
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Publication of MX2020006645A publication Critical patent/MX2020006645A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A61F2013/0296—Apparatus or processes for manufacturing adhesive dressings or bandages for making transdermal patches (chemical processes excluded)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D7/00—Producing flat articles, e.g. films or sheets
    • B29D7/01—Films or sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2071/00—Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
    • B29K2071/02—Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Manufacturing & Machinery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con una preparación percutánea que comprende donepezilo para el tratamiento de la demencia, en donde la preparación comprende: a) donepezilo o su sal farmacéuticamente aceptable como componente activo, b) monocaprilato de propilenglicol como solubilizante, y c) copolímero de bloque de estireno-isopreno-estireno ("SIS") como adhesivo, la preparación de absorción percutánea según la presente invención tiene baja irritación de piel y alta penetración en la piel.
MX2020006645A 2017-12-27 2018-11-07 Preparacion de absorcion percutanea para el tratamiento de la demencia que contiene donepezilo. MX2020006645A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170180647A KR102024996B1 (ko) 2017-12-27 2017-12-27 도네페질을 함유하는 치매 치료용 경피흡수제제
PCT/KR2018/013439 WO2019132229A1 (ko) 2017-12-27 2018-11-07 도네페질을 함유하는 치매 치료용 경피흡수제제

Publications (1)

Publication Number Publication Date
MX2020006645A true MX2020006645A (es) 2020-11-06

Family

ID=67067659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006645A MX2020006645A (es) 2017-12-27 2018-11-07 Preparacion de absorcion percutanea para el tratamiento de la demencia que contiene donepezilo.

Country Status (16)

Country Link
US (1) US11992562B2 (es)
EP (1) EP3733168A4 (es)
JP (1) JP7170728B2 (es)
KR (1) KR102024996B1 (es)
CN (1) CN111542311B (es)
AU (1) AU2018395643B2 (es)
BR (1) BR112020013187A2 (es)
CA (1) CA3087156C (es)
CL (1) CL2020001738A1 (es)
MA (1) MA50116B2 (es)
MX (1) MX2020006645A (es)
PE (1) PE20200863A1 (es)
PH (1) PH12020500568A1 (es)
SA (1) SA520412324B1 (es)
WO (1) WO2019132229A1 (es)
ZA (1) ZA202004530B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102115102B1 (ko) 2018-12-21 2020-05-26 동아에스티 주식회사 안정화된 도네페질 함유 경피 흡수제제
KR102218593B1 (ko) 2020-05-13 2021-02-22 동아에스티 주식회사 안정성이 향상된 도네페질 함유 경피 흡수제제
KR102489860B1 (ko) * 2021-09-02 2023-01-19 동아에스티 주식회사 메만틴 에난트산염을 포함하는 치매 치료용 경피흡수 제제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
JP3987655B2 (ja) 1998-03-03 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬を含有した経皮適用製剤又は坐剤
EP1437130A4 (en) * 2001-10-17 2009-08-26 Hisamitsu Pharmaceutical Co PERCUTANEOUS ABSORPTION PREPARATIONS
DE10159120B4 (de) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
US7744918B2 (en) * 2004-11-22 2010-06-29 Hisamitsu Pharmaceutical Co., Inc. Drug-containing patch
CN101605546B (zh) * 2006-12-01 2011-12-14 日东电工株式会社 抑制含有多奈哌齐的贴剂的经时变色的方法
KR101454362B1 (ko) * 2008-03-24 2014-10-23 아이큐어 주식회사 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
US20100080842A1 (en) 2008-09-30 2010-04-01 Jianye Wen Transdermal extended-delivery donepezil compositions and methods for using the same
CN102630160B (zh) 2009-09-16 2014-05-07 株式会社三养生物制药 透皮递送系统、其制备方法以及使用所述系统的透皮递送方法
RU2545696C2 (ru) * 2009-10-21 2015-04-10 Тейкоку Сейяку Ко., Лтд. Трансдермально абсорбируемый состав, содержащий донепезил
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
EP2564848B1 (en) * 2010-04-28 2015-09-02 Hisamitsu Pharmaceutical Co., Inc. Transdermally absorbable donepezil-containing preparation
US20130224262A1 (en) 2010-09-03 2013-08-29 Medrx Co., Ltd. Transdermal preparation
WO2013035850A1 (ja) * 2011-09-08 2013-03-14 株式会社 ケイ・エム トランスダーム 経皮吸収製剤
KR101239150B1 (ko) 2012-02-28 2013-03-06 에스케이케미칼주식회사 도네페질-함유 경피흡수제제 및 그의 제조방법
KR101485822B1 (ko) 2014-01-22 2015-01-23 주식회사 대웅제약 도네페질 또는 그의 염을 함유하는 경피흡수제제
WO2015127280A1 (en) * 2014-02-20 2015-08-27 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing donepezil
HUE048569T2 (hu) * 2014-12-18 2020-07-28 Icure Pharm Inc Hatóanyagként donepezilt tartalmazó transzdermális készítmény
TW201940199A (zh) * 2018-01-22 2019-10-16 日商鐘化股份有限公司 皮膚貼附用黏著片材

Also Published As

Publication number Publication date
SA520412324B1 (ar) 2024-10-07
BR112020013187A2 (pt) 2020-12-01
PE20200863A1 (es) 2020-08-25
MA50116B2 (fr) 2023-03-31
EP3733168A4 (en) 2021-09-08
PH12020500568A1 (en) 2021-04-19
EP3733168A1 (en) 2020-11-04
RU2020123498A (ru) 2022-01-27
AU2018395643A1 (en) 2020-07-02
CN111542311A (zh) 2020-08-14
MA50116A1 (fr) 2021-09-30
ZA202004530B (en) 2021-09-29
WO2019132229A1 (ko) 2019-07-04
CL2020001738A1 (es) 2020-11-06
RU2020123498A3 (es) 2022-01-27
CN111542311B (zh) 2023-07-14
CA3087156C (en) 2023-08-01
KR102024996B1 (ko) 2019-09-25
JP2021508713A (ja) 2021-03-11
US20210059956A1 (en) 2021-03-04
AU2018395643B2 (en) 2023-02-16
JP7170728B2 (ja) 2022-11-14
KR20190078893A (ko) 2019-07-05
CA3087156A1 (en) 2019-07-04
US11992562B2 (en) 2024-05-28

Similar Documents

Publication Publication Date Title
CY1122603T1 (el) Γαμμα-δικετονες για τη θεραπευτικη αντιμετωπιση και την προληψη της γηρανσης του δερματος και των ρυτιδων
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
PH12018550062A1 (en) Topical film-forming spray
MX378273B (es) Compuestos activos hacia bromodominios.
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
SA519400913B1 (ar) تركيبة موضعية لتعزيز إلتئام الجروح
MX2022005372A (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o mas estatinas.
MX2016011744A (es) Soluciones de buprenorfina de liberacion sostenida.
CL2015002897A1 (es) Inhibidores de bace1
SG10201908500UA (en) Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MX2020006645A (es) Preparacion de absorcion percutanea para el tratamiento de la demencia que contiene donepezilo.
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
WO2018094023A3 (en) Cyclic dipeptides and wound healing
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
IL248468A0 (en) Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
PH12018500258B1 (en) Antibody
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
PH12018502139A1 (en) Phosphaplatin liquid formulations
GEP20217301B (en) Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof
EA201890209A1 (ru) Композиция, содержащая танины